Atopic dermatitis
Conditions
Interventions
Intervention (1-kestose) group Period: 12 weeks Dose: 1g/day (age <
1 year), 2g/day (1-3 years), or 3g/day (4-6 years). A half dose per time, twice per day.
Control (maltose) group Period and dose: same as the intervention group.
Sponsors
Tokai University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with atopic dermatitis 2. "Severe" or milder disease according to the "Guidelines for the Treatment of Atopic Dermatitis 2005" by the Japan Health Labour Sciences Research Group 3. Non-user of external corticosteroids or users of external corticosteroids that are classified as "strong" or weaker.
Exclusion criteria
Exclusion criteria: 1. Users of external corticosteroids that are classified as "very strong" or "stronger" 2. Patients who regularly use probiotics/prebiotics other than 1-kestose for therapeutic purposes 3. Patients who regularly use antibiotics 4. Patients who are judged as ineligible by doctor in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity score based on the Severity Scoring of Atopic Dermatitis (SCORAD) 6 weeks after the begining of the administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. SCORAD scores 12 weeks after the begining of the administration and 6 weeks after the end of the administration 2. Bifidobacterial count and strain structure, staphylococcus aureus count 3. Permeability test of the intestinal mucosa (lactulose/mannitol load test) 4. Bloot tests (white blood cell count, eosinophil count, immunoglobulin E, ImmunoCAP-ovalbumin/milk/mites, Thymus and Activation-Regulated Chemokine) | — |
Countries
Japan
Contacts
Public ContactYasuhiro Koga
Tokai University School of Medicine Laboratory for infectious disease
Outcome results
None listed